

Proton Magnetic Resonance Spectroscopy in Multiple S

Neuroimaging Clinics of North America

19, 45-58

DOI: [10.1016/j.nic.2008.08.002](https://doi.org/10.1016/j.nic.2008.08.002)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Concepts in the Neuropathology and Pathogenesis of Multiple Sclerosis. Canadian Journal of Neurological Sciences, 2010, 37, S5-S15.	0.3	21
2	Advanced magnetic resonance imaging techniques to better understand multiple sclerosis. Biophysical Reviews, 2010, 2, 83-90.	1.5	3
3	Imaging biomarkers in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2010, 31, 770-788.	1.9	121
4	Neuronal and Axonal Degeneration in Experimental Spinal Cord Injury: In Vivo Proton Magnetic Resonance Spectroscopy and Histology. Journal of Neurotrauma, 2010, 27, 599-610.	1.7	36
7	NMR and Pattern Recognition Can Distinguish Neuroinflammation and Peripheral Inflammation. Journal of Proteome Research, 2011, 10, 4428-4438.	1.8	20
8	Advanced MRI in Multiple Sclerosis: Current Status and Future Challenges. Neurologic Clinics, 2011, 29, 357-380.	0.8	31
9	Tumefactive multiple sclerosis: an uncommon diagnostic challenge. Journal of Chiropractic Medicine, 2011, 10, 29-35.	0.3	26
10	Imaging of gray matter lesions in multiple sclerosis. , 2011, , 165-174.		1
12	An object-oriented library for systematic training and comparison of classifiers for computer-assisted tumor diagnosis from MRSI measurements. Computer Science - Research and Development, 2011, 26, 65-85.	2.7	0
13	Energy failure in multiple sclerosis and its investigation using MR techniques. Journal of Neurology, 2011, 258, 2113-2127.	1.8	61
14	Neuroimaging in Multiple Sclerosis: Neurotherapeutic Implications. Neurotherapeutics, 2011, 8, 54-62.	2.1	21
15	Improved spatial coverage for brain 3D PRESS MRSI by automatic placement of outer volume suppression saturation bands. Journal of Magnetic Resonance Imaging, 2011, 33, 792-802.	1.9	21
16	MR Imaging of Multiple Sclerosis. Radiology, 2011, 259, 659-681.	3.6	238
17	Focal multiple sclerosis lesions abound in "normal appearing white matter". Multiple Sclerosis Journal, 2011, 17, 1313-1323.	1.4	39
18	The role of mitochondria in axonal degeneration and tissue repair in MS. Multiple Sclerosis Journal, 2012, 18, 1058-1067.	1.4	60
20	Inflammation High-Field Magnetic Resonance Imaging. Neuroimaging Clinics of North America, 2012, 22, 135-157.	0.5	28
21	New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis. Expert Opinion on Medical Diagnostics, 2012, 6, 109-120.	1.6	9
22	Clinical use of H1 MR spectroscopy in assessment of relapsing remitting and secondary progressive multiple sclerosis. Egyptian Journal of Radiology and Nuclear Medicine, 2012, 43, 257-264.	0.3	3

#	ARTICLE	IF	CITATIONS
23	Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis. PLoS ONE, 2012, 7, e44739.	1.1	16
24	Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration. Journal of Magnetic Resonance Imaging, 2012, 36, 1-19.	1.9	52
25	The role of advanced magnetic resonance imaging techniques in primary progressive MS. Journal of Neurology, 2012, 259, 611-621.	1.8	27
26	Metabolomic approach to human brain spectroscopy identifies associations between clinical features and the frontal lobe metabolome in multiple sclerosis. NeuroImage, 2013, 82, 586-594.	2.1	30
27	¹ H-Magnetic Resonance Spectroscopy in diffuse and focal cervical cord lesions in Multiple Sclerosis. European Radiology, 2013, 23, 3379-3392.	2.3	21
28	¹ H Magnetic Resonance Spectroscopy in Multiple Sclerosis and Related Disorders. Neuroimaging Clinics of North America, 2013, 23, 459-474.	0.5	31
29	The Neurodegenerative Process in Multiple Sclerosis and the Possible Neuroprotective Effect of Treatment with β -Interferon 1a (Avonex). Neuroscience and Behavioral Physiology, 2013, 43, 907-912.	0.2	1
30	Direct effects of secretory products of immune cells on neurons and glia. Journal of the Neurological Sciences, 2013, 333, 30-36.	0.3	9
31	Low Myo-Inositol indicating astrocytic damage in a case series of neuromyelitis optica. Annals of Neurology, 2013, 74, 301-305.	2.8	44
32	Magnetic resonance spectroscopy of the brain. Postgraduate Medical Journal, 2013, 89, 94-106.	0.9	36
33	Metabolic Changes in the Spinal Cord After Brachial Plexus Root Re-implantation. Neurorehabilitation and Neural Repair, 2013, 27, 118-124.	1.4	18
34	Relative metabolite concentrations and ratios determined by use of 3-T region-specific proton magnetic resonance spectroscopy of the brain of healthy Beagles. American Journal of Veterinary Research, 2013, 74, 1291-1303.	0.3	12
35	Serial proton MR spectroscopy of gray and white matter in relapsing-remitting MS. Neurology, 2013, 80, 39-46.	1.5	74
36	Serial proton magnetic resonance spectroscopy of normal-appearing gray and white matter in MS. Neurology, 2013, 80, 17-18.	1.5	7
37	Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia. Neuropsychopharmacology, 2013, 38, 1245-1252.	2.8	60
38	Proton magnetic resonance spectroscopy of human cervical spondylosis at 3T. Spinal Cord, 2013, 51, 558-563.	0.9	31
39	Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2013, 6, 298-310.	1.5	98
40	Examination of Functional Reorganization in Multiple Sclerosis using fMRI Guided Magnetic Resonance Spectroscopy: A Pilot Study. Journal of Multiple Sclerosis, 2013, 01, .	0.1	0

#	ARTICLE	IF	CITATIONS
41	Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI. Multiple Sclerosis International, 2014, 2014, 1-9.	0.4	45
42	Insights from magnetic resonance imaging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 115-149.	1.0	19
43	Clinical Proton MR Spectroscopy in Central Nervous System Disorders. Radiology, 2014, 270, 658-679.	3.6	524
44	Magnetic resonance techniques for investigation of multiple sclerosis. , 2014, , .		2
46	Demyelinating Diseases. , 2015, , 895-905.		0
47	Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra. NMR in Biomedicine, 2015, 28, 505-513.	1.6	20
48	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nature Reviews Neurology, 2015, 11, 597-606.	4.9	422
49	Multi-modal MRI of mild traumatic brain injury. NeuroImage: Clinical, 2015, 7, 87-97.	1.4	82
50	Cognitive Impairment in Multiple Sclerosis. , 2016, , 365-384.		1
51	Fatigue in Multiple Sclerosis: Assessing Pontine Involvement Using Proton MR Spectroscopic Imaging. PLoS ONE, 2016, 11, e0149622.	1.1	16
52	Multiple sclerosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 399-423.	1.0	16
53	Surrogate Markers in Multiple Sclerosis. , 2016, , 163-187.		0
54	Monitoring interferon β treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis. Medicine (United States), 2016, 95, e4782.	0.4	10
55	Differential Neuroproteomic and Systems Biology Analysis of Spinal Cord Injury. Molecular and Cellular Proteomics, 2016, 15, 2379-2395.	2.5	38
56	Progressive multiple sclerosis exhibits decreasing glutamate and glutamine over two years. Multiple Sclerosis Journal, 2016, 22, 112-116.	1.4	40
57	Fast magnetic resonance spectroscopic imaging techniques in human brain- applications in multiple sclerosis. Journal of Biomedical Science, 2017, 24, 17.	2.6	24
58	Proton MR spectroscopy of lesion evolution in multiple sclerosis: Steady-state metabolism and its relationship to conventional imaging. Human Brain Mapping, 2017, 38, 4047-4063.	1.9	18
59	Diagnostic Value of Short and Long Echo Time in 1H-MRS for Patients with Multiple Sclerosis. Applied Magnetic Resonance, 2017, 48, 707-714.	0.6	3

#	ARTICLE	IF	CITATIONS
60	Insight into Metabolic 1H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain Lesions. <i>Frontiers in Neurology</i> , 2017, 8, 454.	1.1	4
61	Patch-Based Super-Resolution of MR Spectroscopic Images: Application to Multiple Sclerosis. <i>Frontiers in Neuroscience</i> , 2017, 11, 13.	1.4	27
62	Machine Learning Approach for Classifying Multiple Sclerosis Courses by Combining Clinical Data with Lesion Loads and Magnetic Resonance Metabolic Features. <i>Frontiers in Neuroscience</i> , 2017, 11, 398.	1.4	48
63	Cerebellum and neurodegenerative diseases: Beyond conventional magnetic resonance imaging. <i>World Journal of Radiology</i> , 2017, 9, 371-388.	0.5	44
64	In Vivo 1H Magnetic Resonance Spectroscopy. <i>Methods in Molecular Biology</i> , 2018, 1718, 151-167.	0.4	8
65	Magnetic Resonance Imaging in Multiple Sclerosis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a028969.	2.9	72
66	Weekly follow up of acute lesions in three early multiple sclerosis patients using MR spectroscopy and diffusion. <i>Journal of Neuroradiology</i> , 2018, 45, 108-113.	0.6	6
67	Cortical Glutamate/GABA Imbalance after Combined Radiation Exposure: Relevance to Human Deep-Space Missions. <i>Neuroscience</i> , 2019, 416, 295-308.	1.1	16
68	Altered hypothalamic metabolism in early multiple sclerosis – MR spectroscopy study. <i>Journal of the Neurological Sciences</i> , 2019, 407, 116458.	0.3	14
69	Evidence for Progressive Microstructural Damage in Early Multiple Sclerosis by Multi-Shell Diffusion Magnetic Resonance Imaging. <i>Neuroscience</i> , 2019, 403, 27-34.	1.1	10
70	Evidence of early microstructural white matter abnormalities in multiple sclerosis from multi-shell diffusion MRI. <i>NeuroImage: Clinical</i> , 2019, 22, 101699.	1.4	27
71	Developing therapeutic strategies to promote myelin repair in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 997-1013.	1.4	13
72	Evaluation of MS related central fatigue using MR neuroimaging methods: Scoping review. <i>Journal of the Neurological Sciences</i> , 2019, 400, 52-71.	0.3	54
73	Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731987995.	0.5	5
74	Effect of Methionine Diet on Metabolic and Histopathological Changes of Rat Hippocampus. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6234.	1.8	15
75	Diffusely Abnormal White Matter, T ₂ Burden of Disease, and Brain Volume in Relapsing&Remitting Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019, 29, 151-159.	1.0	10
76	Spiral MRSI and tissue segmentation of normal-appearing white matter and white matter lesions in relapsing remitting multiple sclerosis patients. <i>Magnetic Resonance Imaging</i> , 2020, 74, 21-30.	1.0	7
77	Current Methods of Magnetic Resonance for Noninvasive Assessment of Molecular Aspects of Pathoetiology in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6117.	1.8	11

#	ARTICLE	IF	CITATIONS
78	A case report revealing acute onset psychosis and cognitive impairment as primary manifestation in relapsingâ€“remitting multiple sclerosis. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 833-836.	0.2	1
79	Molecular Biomarkers in the Cerebrospinal Fluid in Multiple Sclerosis. <i>Neuroscience and Behavioral Physiology</i> , 2020, 50, 527-533.	0.2	1
80	Phosphorus magnetic resonance spectroscopy and fatigue in multiple sclerosis. <i>Journal of Neural Transmission</i> , 2020, 127, 1177-1183.	1.4	2
81	In Vivo Proton Exchange Rate (k_{ex}) MRI for the Characterization of Multiple Sclerosis Lesions in Patients. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 408-415.	1.9	4
82	Pediatric inflammatory demyelinating disorders and mimickers: How to differentiate with MRI?. <i>Autoimmunity Reviews</i> , 2021, 20, 102801.	2.5	9
83	Diagnostic Dilemma: An Atypical Case of Astrocytoma in a Patient with Relapsingâ€“Remitting Multiple Sclerosis. <i>Neurology International</i> , 2021, 13, 240-251.	1.3	1
84	The impact of a lack of mathematical education on brain development and future attainment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	23
85	Inflammationâ€“driven glial alterations in the cuprizone mouse model probed with diffusionâ€“weighted magnetic resonance spectroscopy at 11.7 T. <i>NMR in Biomedicine</i> , 2021, 34, e4480.	1.6	7
86	MR Spectroscopy in Multiple Sclerosis. , 2016, , 151-177.		2
88	Systematic imaging review: Multiple Sclerosis. <i>Annals of Indian Academy of Neurology</i> , 2015, 18, 24.	0.2	20
90	Neuroimaging in Multiple Sclerosis. , 2013, , 43-64.		0
93	High-Field-Strength MRI (3.0 T or More) in White Matter Diseases. , 2017, , 223-237.		0
94	Magnetic Resonance Imaging and Analysis in Multiple Sclerosis. <i>Current Clinical Neurology</i> , 2020, , 109-136.	0.1	3
95	Differentiation of relapsing-remitting and secondary progressive multiple sclerosis: a magnetic resonance spectroscopy study based on machine learning. <i>Arquivos De Neuro-Psiquiatria</i> , 2020, 78, 789-796.	0.3	2
96	Magnetic resonance spectroscopy of the normal appearing grey matter in the posterior cingulate gyrus in the prognosis and monitoring of disease activity in MS patients treated with interferon- β in a 3-year follow-up. <i>Journal of Clinical Neuroscience</i> , 2020, 79, 205-214.	0.8	1
97	Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma. <i>Surgical Neurology International</i> , 2021, 12, 199.	0.2	0
98	Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma. , 2021, 12, 199.		3
99	Correlation between functional MRI techniques and early disability in ambulatory patients with relapsingâ€“remitting MS. <i>Egyptian Journal of Neurology, Psychiatry and Neurosurgery</i> , 2022, 58, .	0.4	0

#	ARTICLE	IF	CITATIONS
100	Whole-Brain Metabolic Abnormalities Are Associated With Mobility in Older Adults With Multiple Sclerosis. <i>Neurorehabilitation and Neural Repair</i> , 2022, 36, 286-297.	1.4	3
101	Predictive MRI Biomarkers in MS – A Critical Review. <i>Medicina (Lithuania)</i> , 2022, 58, 377.	0.8	9
102	Magnetic Resonance Imaging in Primary Progressive Multiple Sclerosis Patients. <i>Clinical Neuroradiology</i> , 2022, 32, 625-641.	1.0	13
103	Metabolic Changes Induced by Cerebral Ischemia, the Effect of Ischemic Preconditioning, and Hyperhomocysteinemia. <i>Biomolecules</i> , 2022, 12, 554.	1.8	3
104	The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 474.	1.8	2
105	Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma. , 2022, 13, 146.		2
106	Spectroscopic analysis of metabolic profile in patients with relapsed multiple sclerosis. <i>Annals of Clinical and Experimental Neurology</i> , 2022, 16, 12-17.	0.1	0
107	Functional Neuroradiology of Multiple Sclerosis: Non-BOLD Techniques. , 2023, , 373-391.		0